Cochlear: The ASX 50 Removal, the Earnings Reset, and Whether the Multiple Has Done Its Work

On September 4, S&P Dow Jones Indices announced that Cochlear has been dropped from the S&P/ASX 50 in the quarterly rebalance. The effective date is September 21. It looks like an index mechanic. It is one — but it is an index mechanic that signals something real. A company that once sat comfortably among Australia's 50 largest firms now carries a market capitalization of around A$8.9 billion, less than a third of what it was a year ago. The stock has fallen roughly 55% over the trailing twelve months, from above A$300 to the A$130s. The index removal is just the marker. The story is the earnings reset beneath it.

What the market has already priced

Cochlear makes cochlear implants — surgical devices that restore hearing for people with severe-to-profound hearing loss. For years it operated with roughly 60% global market share, selling into a demographic tailwind of aging populations and expanding insurance reimbursement. The investment thesis was straightforward: a growing niche, a dominant position, premium pricing, and a platform that could expand with new product launches. The stock earned a P/E ratio in the 50x range, the kind of multiple the market pays for compounding medtech businesses.

That thesis cracked in April 2026. In a trading update that came only two months after Cochlear had published a confident profit forecast, CEO Dig Howitt downgraded full-year 2026 underlying net profit to A$290 million to A$330 million, from a previous range of A$435 million to A$460 million. The shares fell nearly 41% in a single session, hitting A$99.58 — a ten-year low.

The downgrade exposed headwinds across multiple geographies. In the US, volumes declined in March as consumer sentiment hit historic lows, pushing adult and senior patients away from what remains a largely discretionary elective surgery. In Western Europe, NHS waiting lists in the UK, industrial action in Spain, and reimbursement changes in Germany restricted surgical throughput. In the Middle East, conflict threatened order cancellations. In China, reimbursement cuts in special zones reduced premium-tier sales. None of these problems were structural to the product — cochlear implants still work, and the need is still there — but taken together they revealed a business that depends on healthcare system throughput and consumer willingness to act on elective procedures.

What the full year actually delivered

Cochlear's FY2026 results, released in August, confirmed the damage while showing that the second half started to stabilize. Full-year revenue grew just 2% in constant currency to A$2.3 billion. Underlying net profit came in at A$322 million, which meets the midpoint of the April downgrade range but sits well below the company's long-term target of an 18% net profit margin. The actual margin was 14%.

Gross margin fell 3 percentage points to 71%, pressured by a weaker product mix in developed markets, lower factory absorption, foreign exchange headwinds, and pricing pressure from China. Operating expenses rose 5%, with R&D spending jumping 15% to A$323 million — 14% of revenue, up from 12% the year before. The company also began a cloud computing and manufacturing systems program that is expected to cost another A$60 million post-tax. These are costs you don't see going away.

There were offsetting bright spots. Operating cash flow improved by A$130 million year over year and free cash flow more than doubled. Working capital was trimmed, inventory falling A$75 million in the second half after the Nexa platform rollout cleared older stock. The new Nexa implant system now accounts for more than 95% of implant sales in developed markets, with an average price increase of about 3% at launch..

But the dividend was cut. The final dividend for the six months ended June 30 was reduced to A$1.30 per share, down from A$2.15 paid the prior year. A dividend cut on a company that previously raised its payout signals that management expects the pressure to persist, not fade.

The forward view: low single digits

For FY2027, Cochlear guided to low single-digit constant currency revenue growth. Underlying net profit is forecast at A$330 million to A$350 million — a modest improvement from the A$322 million delivered in FY2026, but nothing that suggests a meaningful earnings rebound. Gross margin is expected to stay flat at 70% to 71%, as manufacturing improvements are canceled out by foreign exchange headwinds and the now-annualized lower China pricing. China sales are expected to be in line with FY2026, not growing.

The product pipeline is where Cochlear asks the market to believe the long-term story remains intact. The company has clinical studies underway for a totally implantable cochlear implant — a device with no external components — and for a drug-eluting electrode. These are real technologies, not vapor. But they are also years from commercialization, and they face a competitive landscape that is catching up. Rival MED-EL has already published feasibility study results for its own totally implantable system. Advanced Bionics, owned by Stryker, is another competitor in a market where cochlear implants account for less than A$3 billion in global revenue.

The multiple compression

This is where the rating question lives. Cochlear's trailing P/E ratio has compressed from its historical average of around 55x to roughly 25x based on FY2026 earnings. The forward P/E for FY2027 is approximately the same — 25x on the A$330 million to A$350 million profit guidance. For comparison, the company has traded at 60x to 63x in the past, a multiple that assumed high-single-digit growth and margin expansion. Both of those assumptions are now off the table.

At 25x earnings, the stock is not cheap by value-stock standards. It is cheap relative to Cochlear's own history. The question is whether 25x is the right multiple for a low-single-digit growth medtech company with compressed margins, healthcare system dependency, and a competitive technology threat.

The bear case is straightforward: if Western Europe's healthcare constraints persist, if China's reimbursement pressure deepens, and if MED-EL or Advanced Bionics launch competitive totally implantable systems before Cochlear's TIKI reaches market, then demand growth could stall further and margins could face additional pressure. The dividend cut suggests management is not confident in a near-term recovery. At A$137, the stock has rebounded about 40% from its low of A$88, and the 30-day return after the August earnings was over 20%. That bounce may reflect relief that the worst of the downgrade cycle is over, not conviction that the growth story is back.

The counterargument is that the business impairment is smaller than the valuation reset. Cochlear still holds roughly 60% market share. The Nexa platform has locked in dominant adoption in developed markets. Free cash flow more than doubled, showing the cost base is flexible when revenue slows. The A$130 price level implies the market is pricing in continued stagnation, not decline. If second-half momentum holds, if Nexa software enhancements support share gains, and if the medicalization strategy — converting the self-navigated patient pathway into professionally supported referrals — begins to work, then low-single-digit growth at a 25x multiple could prove adequate.

What would change the read

The stock's next earnings report, expected in early 2027, will be the first real test of whether the stabilization story holds. The numbers that matter: second-half revenue growth (did it hold at the 6% pace, or drift lower?), gross margin (is 71% the floor or can it trend back toward 75%), and any revision to FY2027 guidance. Beyond that, the commercial timeline for Cochlear's totally implantable device and the first major results from MED-EL's competing system will set the competitive overhang for the rest of the decade.

Cochlear has not been broken. It is a company with a dominant product in a real market that is navigating a period of compressed demand and tighter margins. The ASX 50 removal is the visible sign that the market has already downgraded its status. The valuation has followed. Whether 25x earnings is too much for what the business is now, or finally reflects the reset, depends on the next two quarters' evidence. The dividend cut and low guidance suggest there is not enough proof yet to call it a buy. But the multiple is no longer the problem it was a year ago. The question is whether the business catches up.